Please assess the completion status of the following clinical trial:

Trial Title: Boceprevir and Ucalm (St John&Apos;s Wort)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must meet all of the following inclusion criteria within 28 days prior to day 0:~1. The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements~2. Male or non-pregnant, non-lactating females~3. Between 18 to 65 years, inclusive~4. Body Mass Index (BMI) of 18 to 35 kg/m2, inclusive.~5. Women of childbearing potential (WOCBP), who are sexually active, must be using an adequate method of contraception to avoid pregnancy throughout the study and for a period of at least one month after the study in addition to the consistent and correct use of a condom. Examples of adequate methods of contraception for females in this trial are diaphragm with spermicide, substance and intra-uterine device. Hormonal contraceptives should not be considered a method of contraception and should be avoided if containing drospirenone.~6. Willing to consent to their personal details being entered onto The Over volunteering Prevention Scheme (TOPS) database.~7. Registered with a GP in the UK~8. Willing to bring photo ID to each visit~Exclusion Criteria:~Subjects who meet any of the following exclusion criteria are not to be enrolled in this study.~1. Any significant acute or chronic medical illness~2. Evidence of organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, ECG or clinical laboratory determinations~3. Positive blood screen for hepatitis B and/or C antibodies~4. Positive blood screen for HIV-1 and 2 antibodies~5. Current or recent (within three months) gastrointestinal disease~6. Clinically relevant alcohol or drug use (positive urine drug screen) or history of alcohol or drug use considered by the Investigator to be sufficient to hinder compliance with treatment, follow-up procedures or evaluation of adverse events. Smoking is permitted, but tobacco intake should remain consistent throughout the study~7. Exposure to any investigational drug or placebo within three months of first dose of study drug (additional check to be made on TOPS www.tops.org.uk).~8. Consumption of grapefruit or Seville oranges, or any grapefruit or Seville orange containing product within one week of first dose of study drug and for the duration of the study~9. Use of any other drugs, including over-the-counter medications and herbal preparations, within two weeks prior to first dose of study drug, unless approved/prescribed by the Principal Investigator as known not to interact with study drugs (note OCPs containing drosperinone should be excluded)~10. Females of childbearing potential without the use of effective non-hormonal birth control methods, or not willing to continue practising these birth control methods for at least 30 days after the end of the treatment period~11. Previous allergy to any of the constituents of the pharmaceuticals administered in this trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- St John's Wort, then Boceprevir (Type: EXPERIMENTAL): D 1-14 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 52-56 Boceprevir 800mg tds
- Boceprevir, then St John's Wort (Type: EXPERIMENTAL): D 10-14 Boceprevir 800mg tds D 22-35 St. John's Wort 2 x 300mg (Ucalm(r)) QD D 31-35 Boceprevir 800mg tds D 43-56 St. John's Wort 2 x 300mg (Ucalm(r)) QD

Based on this trial design, predict the completion outcome and termination type (if applicable).